Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.

Gift continues donor’s legacy by supporting gastrointestinal research

Ilene Beal
Ilene Beal

Summer 2024
By Alison Krawczyk
Photography by Ilene Beal Charitable Foundation

Throughout her life, Ilene Beal was dedicated to hard work and breaking down barriers. She became a female pioneer in the Boston banking world and was a valued mentor for other women in the industry. When she was diagnosed with cancer in 1997, Beal turned this same commitment toward overcoming the disease. For nearly 10 years, Beal received exceptional care from Jeffrey S. Wisch, MD, who was a senior physician at Dana-Farber Cancer Institute. They developed a relationship based on trust and compassion, and Beal credited Wisch with maximizing her quality of life during her treatment.

Today, the Ilene Beal Charitable Foundation continues Beal’s legacy through its longstanding partnership with Dana-Farber Cancer Institute. With its most recent gift of $525,000, the foundation further supports the previously established Ilene Beal & Jeffrey S. Wisch, MD, Clinical Investigator Fund and Jeffrey S. Wisch, MD, Clinical Investigator Endowment at Dana-Farber. The fund is managed under the direction of Brian Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer.

“I am honored to continue the legacy of Ilene and Dr. Wisch.”

Brian Wolpin, MD, MPH

“I am honored to continue the legacy of Ilene and Dr. Wisch,” said Wolpin. “By channeling their generous spirits, the team and I are emboldened to continue our critical work improving outcomes for patients and their families who face gastrointestinal cancer.”

These funds support research that is integral to the mission of Dana-Farber at large, and particularly the Gastrointestinal Cancer Center, as they support the talented physicians working to identify new treatments for patients with gastrointestinal cancer.

The endowment enables the work of Dana-Farber physicians who are focused on patient-centered research, which is essential to understanding and establishing the safety and effectiveness of new treatments and to guide physicians to prescribe the right drug, for the right patient, at the right time.

, ,

More stories:

Copy link
Powered by Social Snap